Novartis Approaches $12 Billion Acquisition of Avidity Biosciences
TL;DR Summary
Novartis is set to acquire Avidity Biosciences for $12 billion, marking a significant move in the pharmaceutical industry.
Topics:top-news#acquisition#avidity-biosciences#business#mergers-and-acquisitions#novartis#pharmaceuticals
- Novartis to buy Avidity Biosciences for $12bn Financial Times
- Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash CNBC
- Novartis Said to Near at Least $70-Per-Share Deal for Avidity Bloomberg.com
- Novartis to buy RNA-focused Avidity in $12B deal statnews.com
- Novartis is said to near acquisition of Avidity Biosciences for more than $70 a share (NVS:NYSE) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
87%
137 → 18 words
Want the full story? Read the original article
Read on Financial Times